Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Study sponsor: Inovio Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-09-13Actual
Enrollment · participants1307Actual
Source updated2023-12-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.